retatrutide phase 2 obesity trial results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon
Pay in 4 interest-free payments of $5.08 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4






















